Good company with new technology - Seems like we finally have hit the floor, now ready for a bullish move to the upside.
I will be shorting Arcturus Therapeutics to a range of $10-$12, and exit there.
Arcturus Therapeutics Holdings Inc. $ARCT is set to be EBITDA positive in 2022 with a massive change in its revenue from 24.05M in 2021 to 326.44M in 2022. This is 12.57x increase in revenue. These numbers are estimates, but even with a large error margin we should see a drastic change in the price. Moreover, the decline from ATH was 80% and the price has been in...
Monthly candle right around historical S+R, a monthly and or weekly close above $34.50 takes ARCT to $44ish. Could be fire
Backtest + clean bounce off last year's gap up breakout. Oversold and ready for reversal, very fire
ARCT fell a whopping 66% the past 2 days. The catalyst was the inability of its COVID vaccine to produce levels of antibodies comparable to other vaccines in development or already developed. You can check more here: www.investors.com It found support around $41.5 and moved about 12% to the upside to only fall again. It is currently hovering over the $44.3...